12 HR carbamazepine 200 MG Extended Release Oral Capsule — RxCUI 200133
RxNorm drug concept · Semantic clinical drug
RxCUI 200133
Semantic clinical drug · SCD
● Current RxNorm concept 19 FDA products
19 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI200133
Official name12 HR carbamazepine 200 MG Extended Release Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascarBAMazepine 200 MG 12HR Extended Release Oral Capsule
FDA products mapped19
Package NDCs mapped19
Reported Medicaid activity (SDUD)67,133 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Carbamazepine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- That depends on why your doctor prescribed it. If you have epilepsy, it helps prevent certain types of seizures by calming overactive electrical signals in the brain. If you have t...
- What exactly is carbamazepine supposed to do for me?
- Please don't stop it suddenly without talking to your doctor first — this is really important. Stopping carbamazepine abruptly can trigger serious seizures or even a dangerous cond...
- Can I just stop taking it if I feel better or if I don't like the side effects?
🕸️ Concept Web — How 12 HR carbamazepine 200 MG Extended Release Oral... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
12 HR carbamazepine 200 MG Extended Release Oral Capsule
RxCUI 200133 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Carbamazepine
2002IN
-
Carbamazepine
-
Brand names 2
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Carbatrol
215879BN -
Equetro
583135BN
-
Carbatrol
-
Dose forms 12
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Carbamazepine Extended Release Oral Capsule
485799SCDF -
Carbamazepine Oral Product
1155760SCDG -
Carbamazepine Pill
1155761SCDG -
Carbamazepine Extended Release Oral Capsule [Carbatrol]
367066SBDF -
Carbamazepine Extended Release Oral Capsule [Equetro]
583137SBDF -
Carbatrol Oral Product
1174376SBDG -
Carbatrol Pill
1174377SBDG -
Equetro Oral Product
1168245SBDG - +4 more in this family
-
Carbamazepine Extended Release Oral Capsule
-
Clinical & branded drugs 5
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Carbamazepine 200 MG
315565SCDC -
12 HR carbamazepine 200 MG Extended Release Oral Capsule [Carbatrol]
308977SBD -
12 HR carbamazepine 200 MG Extended Release Oral Capsule [Equetro]
672910SBD -
Carbamazepine 200 MG [Carbatrol]
571790SBDC -
Carbamazepine 200 MG [Equetro]
583139SBDC
-
Carbamazepine 200 MG
Showing up to 8 concepts per family — 16 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Carbamazepine 200 MG
SCDC · 315565 -
Carbamazepine Extended Release Oral Capsule
SCDF · 485799 -
Carbamazepine Oral Product
SCDG · 1155760 -
Carbamazepine Pill
SCDG · 1155761
Brand-Name Concepts
-
12 HR carbamazepine 200 MG Extended Release Oral Capsule [Carbatrol]
SBD · 308977 -
12 HR carbamazepine 200 MG Extended Release Oral Capsule [Equetro]
SBD · 672910 -
Carbamazepine 200 MG [Carbatrol]
SBDC · 571790 -
Carbamazepine 200 MG [Equetro]
SBDC · 583139 -
Carbamazepine Extended Release Oral Capsule [Carbatrol]
SBDF · 367066 -
Carbamazepine Extended Release Oral Capsule [Equetro]
SBDF · 583137 -
Carbatrol Oral Product
SBDG · 1174376 -
Carbatrol Pill
SBDG · 1174377 -
Equetro Oral Product
SBDG · 1168245 -
Equetro Pill
SBDG · 1168246
📦 FDA Products & Package NDCs
19 products · 19 package NDCs
19 package NDCs map to RxCUI 200133 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00904-6885-04 | 30 BLISTER PACK in 1 CARTON (0904-6885-04) / 1 CAPSULE, EXT... | Carbamazepine | Major Pharmaceuticals | 2012-03-23 |
| 30698-0419-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (30698-419-12) | EQUETRO | Validus Pharmaceuticals LLC | 2004-12-10 |
| 30698-0421-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (30698-421-12) | EQUETRO | Validus Pharmaceuticals LLC | 2004-12-10 |
| 30698-0423-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (30698-423-12) | EQUETRO | Validus Pharmaceuticals LLC | 2004-12-10 |
| 50268-0170-13 | 30 BLISTER PACK in 1 BOX (50268-170-13) / 1 CAPSULE, EXTEND... | Carbamazepine | AvPAK | 2021-10-19 |
| 50268-0171-13 | 30 BLISTER PACK in 1 BOX (50268-171-13) / 1 CAPSULE, EXTEND... | Carbamazepine | AvPAK | 2021-10-19 |
| 50268-0172-13 | 30 BLISTER PACK in 1 BOX (50268-172-13) / 1 CAPSULE, EXTEND... | Carbamazepine | AvPAK | 2021-10-19 |
| 54092-0171-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (54092-171-12) | Carbatrol | Takeda Pharmaceuticals America, Inc. | 1999-12-22 |
| 54092-0172-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (54092-172-12) | Carbatrol | Takeda Pharmaceuticals America, Inc. | 1997-09-30 |
| 54092-0173-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (54092-173-12) | Carbatrol | Takeda Pharmaceuticals America, Inc. | 1997-09-30 |
| 60505-2805-07 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (60505-2805-7) | Carbamazepine | Apotex Corp. | 2012-03-23 |
| 60505-2806-07 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (60505-2806-7) | Carbamazepine | Apotex Corp. | 2012-03-23 |
| 60505-2807-07 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (60505-2807-7) | Carbamazepine | Apotex Corp. | 2012-03-23 |
| 62559-0484-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62559-484-12) | Carbamazepine | ANI Pharmaceuticals, Inc. | 2026-04-13 |
| 62559-0485-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62559-485-12) | Carbamazepine | ANI Pharmaceuticals, Inc. | 2026-04-13 |
| 62559-0486-12 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62559-486-12) | Carbamazepine | ANI Pharmaceuticals, Inc. | 2026-04-13 |
| 67046-1559-03 | 30 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (67046-1559-3... | Carbamazepine | Coupler LLC | 2025-04-29 |
| 71335-2706-01 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71335-2706-1) | Carbamazepine | Bryant Ranch Prepack | 2025-07-28 |
| 71335-3002-01 | 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (71335-3002-1) | Carbamazepine | Bryant Ranch Prepack | 2025-11-05 |
Observed labelers:
ANI Pharmaceuticals, Inc. (3) ·
Apotex Corp. (3) ·
AvPAK (3) ·
Takeda Pharmaceuticals America, Inc. (3) ·
Validus Pharmaceuticals LLC (3) ·
Bryant Ranch Prepack (2)
· +2 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.